No. Cardarine (GW-501516) is a PPARδ receptor agonist, completely different from SARMs. It works by activating peroxisome proliferator-activated receptor delta, increasing mitochondrial biogenesis and fatty acid oxidation. Often grouped with SARMs because of similar use cases in fitness communities.

What did the mouse endurance studies show?

In mice, Cardarine increased running endurance by 68% after just 4 weeks. The mechanism involves massive upregulation of genes involved in fatty acid oxidation, leading to the body preferring fat as fuel during exercise.

Controversial. Long-term rat studies at high doses showed cancer tumor growth. GSK abandoned development in 2007. However, short-term human trials for metabolic disorders showed reasonable safety. The cancer findings are dose-dependent and concerning.

PPARδ Agonist • NOT a SARM • GSK Abandoned

Cardarine (GW-501516): The Endurance Compound

By MeetPeptide Research Team

Last updated: March 2026

NOT a SARM — it's a PPARδ agonist. 68% endurance increase in mice, incredible lipid profile improvements, but also cancer concerns that caused GSK to walk away in 2007. Here's the full research.

Common Research Dose
(Daily)

Endurance Increase
(Mice, 4 Weeks)

Elimination Half-Life
(Daily Dosing)

⚠️ Regulatory Status & Safety Warning

Cardarine is NOT a SARM and NOT FDA approved. It's a PPARδ agonist developed for metabolic disorders. GSK abandoned development in 2007 after long-term rat studies showed cancer tumor growth at high doses.

All SARMs and this compound are banned by WADA in competitive sport. This page is for educational purposes only.

NOT FDA APPROVED WADA BANNED CANCER CONCERN

Mechanism

How Cardarine Works

Completely different from SARMs. Cardarine activates PPARδ (peroxisome proliferator-activated receptor delta), dramatically increasing mitochondrial biogenesis and fatty acid oxidation.

🎯

PPARδ Receptor Activation

Activates peroxisome proliferator-activated receptor delta. This increases expression of genes involved in fatty acid transport and oxidation. The body switches to burning fat as primary fuel, sparing glycogen for later.

🏃

68% Endurance Increase (Mice)

4 weeks of Cardarine increased running time to exhaustion by 68% in mice. Effects seen within weeks. Upregulation of PGC-1α and mitochondrial genes in muscle tissue drives this dramatic endurance enhancement.

🫀

Lipid Profile Improvement

Significant reductions in triglycerides, LDL, and total cholesterol. Increases HDL in some studies. Originally developed for dyslipidemia and metabolic syndrome treatment before GSK abandoned it.

⚠️

Cancer Concern (GSK Abandoned)

2-year rat studies at high doses showed increased tumor incidence. GSK stopped development in 2007. The cancer risk appears dose-dependent. Human short-term trials didn't show this, but long-term data is lacking.

Research Data

What the Research Shows

Data context: Most dramatic data comes from rodent studies. Human metabolic trials showed safety over 12 weeks but were not designed to detect cancer risk. The cancer findings led to complete program abandonment.

Running Time to Exhaustion (Mice, 4 weeks)

Nagai et al. — dramatic endurance enhancement via PGC-1α

Triglyceride Reduction

Significant reduction in dyslipidemic subjects

HDL Cholesterol Increase

Modest increase observed in human trials

Tumor Incidence (High Dose, 2-Year Rats)

GSK abandoned after cancer findings at high doses

Safety

Side Effects & Risks

⚠️ Cancer Risk

2-year rat studies: tumor growth at high doses
GSK abandoned program in 2007
Dose-dependent effect observed
Human short-term trials: no cancer (but limited duration)
Unknown risk at research doses

Other Effects

Headaches reported
Fatigue in some users
Possible liver enzyme changes
Joint pain anecdotal
Generally well-tolerated short-term

Sources

Study Citations

Endurance Study (Mice)

Activation of PPARδ improves endurance capacity in rodents

Nagai et al., Proc Natl Acad Sci USA, 2005

GSK Development

GW501516 program abandoned due to cancer findings in long-term rodent studies

GlaxoSmithKline, 2007

Human Safety Trial

Phase 1/2 safety and pharmacokinetics of GW501516

Olson et al., J Clin Pharmacol, 2012

Bottom Line

Key Takeaways

✅ What We Know

NOT a SARM — PPARδ agonist with different mechanism
68% endurance increase in mice is remarkable
Significant lipid/triglyceride improvements
GSK abandoned after cancer findings
WADA banned in sport

⚠️ What We Don't Know

Cancer risk at human research doses
Long-term human safety data
Quality of research chemical supply
Optimal dosing for endurance (vs metabolic)
Interaction with other compounds

🔬 Verified Research Source

Third-party tested compounds from Swiss Chems — one of the most trusted research suppliers.

🧬 Cardarine GW-501516 Buy from Swiss Chems — Lab-tested, verified purity → Shop Now

Affiliate link — supports MeetPeptide at no extra cost. All Swiss Chems products include third-party lab testing certificates.

Cardarine (GW-501516): The Endurance Compound

How Cardarine Works

What the Research Shows

Side Effects & Risks

Study Citations

Key Takeaways

🔬 Verified Research Source

🛒 Recommended Products

More Research

Want the Complete Protocol Guide?